USFDA concludes inspection at Cipla arm InvaGen's New York facility with 'zero' observations
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓The USFDA concluded a routine inspection at Cipla arm InvaGen’s New York facility with zero observations.
- ✓Cipla said the check happened in Hauppauge from October 19-22, 2026.
- ✓The company noted, "The inspection concluded with zero Form 483 observations." This result shows the plant met all required manufacturing standards during the visit.
Story at a Glance
- Category
- BUSINESS
- Reported By
- Business Line
- Reading Speed
- 1 Minute(s)
- Market Focus
- India Economy
Drug major Cipla on Friday said the United States Food and Drug Administration (USFDA) concluded a routine inspection at the manufacturing facility of its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., in the US with 'zero' Form 483 observations.
The USFDA issues a Form 483 to a company's management at the conclusion of an inspection to notify them of any objectionable conditions or potential non-compliance observed regarding manufacturing processes, facilities or controls.
The routine current Good Manufacturing Practices (cGMP) inspection was conducted by the US health regulator at the manufacturing facility in Hauppauge, Long Island, New York, from October 19-22, 2026, Cipla said in a regulatory filing.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Business Line
Read the full, original unfiltered story directly on the publisher's portal.